Background: Limited data are available for the use of agents in metastatic castration-resistant prostate cancer (mCRPC) beyond the third-line. We provide data during treatment with cabazitaxel (CAB), helping to improve the informed-consent process. Patients and Methods: We retrospectively reviewed patients treated with fourth-line or beyond CAB for mCRPC after failure of previous therapies with docetaxel, abiraterone acetate, enzalutamide and/or radium-223. The progression-free survival (PFS) and the overall survival (OS) were estimated using the Kaplan-Meier method and compared to published data based on a structured literature review. The hospitalization rate was recorded. Factors influencing 6-months OS were analyzed. Results: Fifteen patients were identified at 4 institutions and included in the analysis. The median PFS was 104 days (range 47-397 days). The median time to death was 10 months (range 2-16). PFS and OS data are in accordance with 17 published patients so far. During the therapy, eleven (73%) of the patients were hospitalized. Prostate-specific antigen (PSA, 500 units; hazards ratio [HR] 1.491, 95% CI 1.000-2.0175), white blood cell count (HR 0.425, 95% CI 0.108-0.952), hemoglobin (HR 0.6014, 95% CI 0.2942-1.0758), and alkaline phosphatase (100 units; HR 1.0964, 95% CI 1.000-1.2859) correlate with 6-months OS. Conclusions: CAB beyond the third-line is often accompanied by hospitalization. PFS is a significant proportion of the median time of OS. The baseline laboratory might be a good indicator for the decision between CAB and best-supportive care.

Keywords:
Cabazitaxel, Fourth-line, Castration-resistant prostate cancer, Response rate, Hospitalization
1.
Siegel RL, Miller KD, Jemal A: Cancer statistics, 2016. CA Cancer J Clin 2015;66:7-30.
2.
Halabi S, Kelly WK, Ma H, Zhou H, Solomon NC, Fizazi K, et al: Meta-analysis evaluating the impact of site of metastasis on overall survival in men with castration-resistant prostate cancer. J Clin Oncol 2016;34:1652-1659.
3.
Lorente D, Mateo J, Perez-Lopez R, de Bono JS, Attard G: Sequencing of agents in castration-resistant prostate cancer. Lancet Oncol 2015;16:e279-e292.
4.
Balogh EP, Ganz PA, Murphy SB, Nass SJ, Ferrell BR, Stovall E: Patient-centered cancer treatment planning: improving the quality of oncology care. Summary of an Institute of Medicine workshop. Oncologist 2011;16:1800-1805.
5.
de Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels JP, Kocak I, et al: Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 2010;376:1147-1154.
6.
de Bono JS, Hardy-Bessard AC, Kim CS, Geczi L, Ford D, Mourey L, et al: Phase III non-inferiority study of cabazitaxel (C) 20 mg/m2 (C20) versus 25 mg/m2 (C25) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel (D). J Clin Oncol 2016;34(suppl; abstr 5008).
7.
Caffo O, De Giorgi U, Fratino L, Alesini D, Zagonel V, Facchini G, et al: Clinical outcomes of castration-resistant prostate cancer treatments administered as third or fourth line following failure of docetaxel and other second-line treatment: results of an Italian multicentre study. Eur Urol 2015;68:147-153.
8.
Pezaro CJ, Omlin AG, Altavilla A, Lorente D, Ferraldeschi R, Bianchini D, et al: Activity of cabazitaxel in castration-resistant prostate cancer progressing after docetaxel and next-generation endocrine agents. Eur Urol 2014;66:459-465.
9.
Yabroff KR, Lamont EB, Mariotto A, Warren JL, Topor M, Meekins A, et al: Cost of care for elderly cancer patients in the United States. J Natl Cancer Inst 2008;100:630-641.
10.
Morden NE, Chang CH, Jacobson JO, Berke EM, Bynum JP, Murray KM, et al: End-of-life care for Medicare beneficiaries with cancer is highly intensive overall and varies widely. Health Aff (Millwood) 2012;31:786-796.
11.
Brierly RD, O'Brien TS: The Importance of Palliative Care in Urology. Urol Int 2008;80:13-18.
12.
Brooks GA, Kansagra AJ, Rao SR, Weitzman JI, Linden EA, Jacobson JO: A clinical prediction model to asssess risk for chemotherapy-related hospitalization in patients initiating palliative chemotherapy. JAMA Oncol 2015;1:441-447.
13.
Hassett MJ, Rao SR, Brozovic S, Stahl JE, Schwartz JH, Maloney B, et al: Chemotherapy-related hospitalization among community cancer center patients. Oncologist 2011;16:378-387.
14.
Kolodziej M, Hoverman JR, Garey JS, Espirito J, Sheth S, Ginsburg A, et al: Benchmarks for value in cancer care: an analysis of a large commercial population. J Oncol Pract 2011;7:301-306.
15.
Gillessen S, Omlin A, Attard G, de Bono JS, Efstathiou E, Fizazi K, et al: Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015. Ann Oncol 2016;pii:mdw180.
16.
Al Nakouzi N, Le Moulec S, Albigès L, Wang C, Beuzeboc P, Gross-Goupil M, et al: Cabazitaxel remains active in patients progressing after docetaxel followed by novel androgen receptor pathway targeted therapies. Eur Urol 2015;68:228-235.
17.
Pezaro CJ, Omlin AG, Altavilla A, Lorente D, Ferraldeschi R, Bianchini D, et al: Activity of cabazitaxel in castration-resistant prostate cancer progressing after docetaxel and next-generation endocrine agents. Eur Urol 2014;66:459-465.
18.
Sella A, Sella T, Peer A, Berger R, Frank SJ, Gez E, et al: Activity of cabazitaxel after docetaxel and abiraterone acetate therapy in patients with castration-resistant prostate cancer. Clin Genitourin Cancer 2014;12:428-432.
19.
Saad F, Winquist E, Hubay S, Berry S, Assi H, Levesque E, et al: Efficacy, quality of life, and safety of cabazitaxel in Canadian metastatic castration-resistant prostate cancer patients treated or not with prior abiraterone. Can Urol Assoc J 2016;10:102-109.
20.
van Soest RJ, Nieuweboer AJM, de Morrée ES, Chitu D, Bergman AM, Goey SH, et al: The influence of prior novel androgen receptor targeted therapy on the efficacy of cabazitaxel in men with metastatic castration-resistant prostate cancer. Eur J Cancer 2015;51:2562-2569.
21.
Sonpavde G, Bhor M, Hennessy D, Bhowmik D, Shen L, Nicacio L, et al: Sequencing of cabazitaxel and abiraterone acetate after docetaxel in metastatic castration-resistant prostate cancer: treatment patterns and clinical outcomes in multicenter community-based US oncology practices. Clin Genitourin Cancer 2015;13:309-318.
22.
Wissing MD, Coenen JL, van den Berg P, Westgeest HM, van den Eertwegh AJ, van Oort IM, et al: CAST: A retrospective analysis of cabazitaxel and abiraterone acetate sequential treatment in patients with metastatic castrate-resistant prostate cancer previously treated with docetaxel. Int J Cancer 2015;136:E760-E772.
23.
Heidenreich A, Scholz HJ, Rogenhofer S, Arsov C, Retz M, Müller SC, et al: Cabazitaxel plus prednisone for metastatic castration-resistant prostate cancer progressing after docetaxel: results from the German compassionate-use programme. Eur Urol 2013;63:977-982.
24.
Basch E, Iasonos A, McDonough T, Barz A, Culkin A, Kris MG, et al: Patient versus clinician symptom reporting using the national cancer institute common terminology criteria for adverse events: results of a questionnaire-based study. Lancet Oncol 2006;7:903-909.
25.
Brooks GA, Li L, Uno H, Hassett MJ, Landon BE, Schrag D: Acute hospital care is the chief driver of regional spending variation in Medicare patients with advanced cancer. Health Aff (Millwood) 2014;33:1793-1800.
26.
Schmitz-Dräger BJ, Weiss C, Ebert T, Dörsam J, Bismarck E: Skeletal-related events in metastatic prostate cancer and the number needed to treat: a critical consideration. Urol Int 2013;90:329-333.
27.
Halabi S, Lin CY, Small EJ, Armstrong AJ, Kaplan EB, Petrylak D, et al: Prognostic model predicting metastatic castration-resistant prostate cancer survival in men treated with second-line chemotherapy. J Natl Cancer Inst 2013;105:1729-1737.
28.
Takaha N, Okihara K, Kamoi K, Hongo F, Iwata T, Yano K, et al: Feasibility of tri-weekly docetaxel-based chemotherapy for elderly patients (age 75 and older) with castration-resistant prostate cancer. Urol Int 2011;87:263-269.
29.
Extermann M, Boler I, Reich RR, Lyman GH, Brown RH, DeFelice J, et al: Predicting the risk of chemotherapy toxicity in older patients: the Chemotherapy Risk Assessment Scale for High-Age Patients (CRASH) score. Cancer 2012;118:3377-3386.
© 2017 S. Karger AG, Basel
2017
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.